About Hyfinity Investments
Hyfinity Investments is a venture capital firm founded in 2016. It is primarily based out of Beijing, China. As of Jan 2025, Hyfinity Investments has invested in 47 companies. It primarily invests in Series A round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Seed round of Jianda Biopharmaceuticals Overall, Hyfinity Investments portfolio has seen 4 IPOs and 1 acquisition including key companies like CureVac, Oculis and Clarus Therapeutics. A lot of funds co-invest with Hyfinity Investments, with names like BioVeda China Fund sharing a substantial percentage of its portfolio. Hyfinity Investments has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Hyfinity Investments' List of Top Investments
Hyfinity Investments has a portfolio of 47 companies. Their most notable investments are in Beijing Shurui Technology and Immunowake.Their portfolio spans across China, United States, Singapore and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series A, Seed and 3 more. Here is the list of top investments by Hyfinity Investments:1. CureVac
Developer of mRNA-based therapeutics against cancer and infectious diseases. It has developed RNAntibody to enable the expression of functional antibodies and antibody-like proteins from mRNA. The lead product includes CV9104, an investigational therapeutic vaccine to treat prostate cancer. The vaccine is injected into the skin to stimulate the body's immune system to destroy prostate cancer cells. The company's other product includes CV8102 for cutaneous myeloma and CV9202 used to treat patients with non-small cell lung cancer.
Key facts about CureVac
- Founded Year: 2000
- Location: Tubingen (Germany)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $975M
- Employee Count: 646 as on Mar 31, 2026
- Investors: Baillie Gifford, Qatar Investment Authority and 16 Others
- Latest Funding Round: Grant (prize money), Sep 15, 2020, $*****
- Highlight: Acquired
Developer of CAR-T cell therapies for blood cancers and solid tumors. The company has a CoupledCAR technology platform to develop a pipeline of drugs for colorectal, thyroid, pancreatic, and lung cancer.
Key facts about Innovative Cellular Therapeutics
- Founded Year: 2009
- Location: Shanghai (China)
- Stage: Series C
- Total Funding till date: $97.1M
- Employee Count: 14 as on Feb 28, 2026
- Investors: ShenZhen GTJA Investment Group, SBCVC and 5 Others
- Latest Funding Round: Series C, Sep 06, 2021, $*****
- Highlight: Editors' Pick
3. Oculis
Developer of therapeutics for the treatment of ophthalmic conditions. The company's product line include OCS-01 is a non-invasive topical formulation based on solubilizing nanoparticle technology. It is used for the treatment of diabetic macular edema, post-surgery cataract inflammation, and dry eye.
Key facts about Oculis
- Founded Year: 2003
- Location: Pully (Switzerland)
- Stage: Public
- Total Funding till date: $93.2M
- Employee Count: 2 as on Dec 31, 2021
- Investors: Pivotal bioVenture Partners China, Bay City Capital and 13 Others
- Latest Funding Round: Post IPO, Apr 12, 2024, $*****
- Highlight: Public
4. Inxmed
Developer of treatments for drug resistance and metastases in solid tumors. The company offers a chemotherapy approach and has its lead product IN10018 in phase 2 of the clinical study. It offers the treatment of platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer by focal adhesion kinase (FAK) inhibitor. The company is also in Phase I of the clinical trial of IN10018 single agent and combined chemotherapy for the treatment of gastric cancer.
Key facts about Inxmed
- Founded Year: 2018
- Location: Shanghai (China)
- Stage: Series B
- Total Funding till date: $84M
- Employee Count: 16 as on Feb 28, 2026
- Investors: CD Capital, Hyfinity Investments and 7 Others
- Latest Funding Round: Conventional Debt, Jul 21, 2022, $*****
- Highlight: Editors' Pick
5. Binhui Bio
Developer of oncolytic virus-based drugs. The company focuses on the research and development of an oncolytic virus (oHSV2) technology platform, and its first product, BS001 (OH2) injection, a multi-indication single drug, and combination drug to treat various solid tumors.
Key facts about Binhui Bio
- Founded Year: 2010
- Location: Wuhan (China)
- Stage: Series C
- Total Funding till date: $158M
- Investors: DNV Capital, Vertex Ventures and 11 Others
- Latest Funding Round: Series C, Apr 24, 2022, $*****
- Highlight: Editors' Pick
Hyfinity Investments' Year-on-Year Investment Trends
Hyfinity Investments has invested in 47 companies over the last 7 years, with an average of 1 new investment annually in the last 5 years. In 2025, it made 1 investment. Its most recent first time investment was in Jianda Biopharmaceuticals and most recent follow-on round was in Nuo-Meier.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 0 | 0 | 0 |
2023 | 1 | 1 | 2 |
2022 | 2 | 0 | 2 |
2021 | 3 | 0 | 3 |
2020 | 0 | 0 | 0 |
2019 | 2 | 0 | 2 |
Hyfinity Investments' Investments by Stage
Hyfinity Investments has made 3 investments in Series A stage with an average round size of $21.2M, 2 investments in Seed stage with an average round size of $16.8M, 2 investments in Series B stage with an average round size of $57.5M, 1 investment in Series C stage with an average round size of $57M and 1 investment in Unattributed stage.Stage of entry | No. of Investments |
|---|---|
Series A | 3 |
Seed | 2 |
Series B | 2 |
Series C | 1 |
Unattributed | 1 |
Note: We have considered here, only first round of investments
Hyfinity Investments' Investments by Sector
Hyfinity Investments has a diverse portfolio, with companies operating in the Life Sciences, Healthcare, High Tech and Robotics - Industry Applications. Notably, it has invested in 33 Enterprise (B2B) companies, 29 Tech companies, 7 Tech hardware companies and at least 5 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
Healthcare | 2 |
High Tech | 1 |
Robotics - Industry Applications | 1 |
Note: We have considered here, only first round of investments
Hyfinity Investments' Investments by Geography
Hyfinity Investments has made most investments in China (6), followed by United States where it has made 1 investment.Country | No. of Investments |
|---|---|
China | 6 |
Singapore | 1 |
Switzerland | 1 |
United States | 1 |
Note: We have considered here, only first round of investments
Hyfinity Investments' recent investments
Hyfinity Investments has not made any investment in 2026 so far.Here are the most recent investments by Hyfinity Investments:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 14, 2025 | China | Seed | 3317 | - | |
Aug 15, 2023 | China | Series A | 1673 | [+3] | |
Mar 07, 2023 | China | Series B | 7586 | [+4] | |
May 15, 2022 | United States | Seed | 6291 | ||
May 08, 2022 | China | Series B | 7599 | - |
IPOs and Publicly Listed companies in Hyfinity Investments' Portfolio
4 of Hyfinity Investments' portfolio companies have become public. Oculis got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Mar 2023 and Puri Eye Hospital got listed on the Shenzhen Stock Exchange (SZSE) at marketcap of $751M.Here are Hyfinity Investments' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 03, 2023 | May 04, 2021 | Series C | 9473 | |
Jul 05, 2022 | - | - | 4577 | |
Dec 25, 2016 | - | - | 5001 | |
- | - | - | 3491 |
Acquired companies in Hyfinity Investments' Portfolio
1 company from Hyfinity Investments' portfolio has been acquired. The most recent acquisition were CureVac in Jun 2025 by BioNTech for $1.25B.Here are Hyfinity Investments' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 12, 2025 | - | - | 3419 |
Team profile of Hyfinity Investments
Hyfinity Investments has a team of 2 members. Hyfinity Investments' team does not sit on the board of any company as of now.Co-investors of Hyfinity Investments
Over the past 7 years, 58 investors have co-invested in Hyfinity Investments's portfolio companies. This includes only funds.
- Invested before Hyfinity Investments: Bay City Capital, Novartis Venture Fund and 15 others have invested in rounds before Hyfinity Investments. There is 1 company where Bay City Capital has invested before Hyfinity Investments and 1 company where Novartis Venture Fund has invested before Hyfinity Investments.
- Top Co-investors of Hyfinity Investments: 24 investors entered a company along with Hyfinity Investments. These include investors like BioVeda China Fund (1 company).
- Invested after Hyfinity Investments: A total of 17 investors have invested in Hyfinity Investments's portfolio after their investments. Top Investors include SPD Silicon Valley Bank (1 company), Greater Bay Area Homeland Investments (1 company) and Cormorant Asset Management (1 company).
Recent News related to Hyfinity Investments
•
•
DPM Closes $28 Million Series C FinancingG-MedTech•Jan 24, 2024•Yunqi Partners, Infinity Investing, Dpm, Beijing Digital Precision Medical Technology and 1 other
•
DPM company completes over 200 million yuan C financing, Daohe Zhizhi InvestmentPEdaily•Jan 22, 2024•Dpminstrument, Gree Holdings, SBCVC, Beijing Digital Precision Medical Technology and 1 other
•
Cascade completed a Series A funding of 140 million CNYEqualOcean•Aug 15, 2023•Puhua Capital, Hyfinity Investments, NNFE, Cascade Pharmaceuticals
•
•
Cargene Closes a US$19.2M Pre-A Round Led by BioTrack CapitalPR Newswire•Dec 14, 2021•Lerna Biopharma, BioTrack Capital, Hyfinity Investments, Legend Star and 1 other
•
•
•
Oculis Announces Financing to Advance Therapies for Anterior SegmentEyewire•May 04, 2021•Oculis, BioVeda China Fund, Hyfinity Investments, VI Partners and 10 others
•
Elpiscience gets corporate help in $100m roundGlobal Corporate Venturing•Dec 30, 2019•Tencent, LAV Asset Management, Elpiscience, Lilly and 12 others
